Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin

Clinical Cancer Research

Volumn 5, Issue 1, 1999, Pages 197-202

  Ruan, Sanbao ^a   Okcu, M Fatih ^a   Pong, Rey Chen ^b   Andreeff, Michael ^a   Levin, Victor ^a   Hsieh, Jer Tsong ^b   Zhang, Wei ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; PROTEIN; VIRUS VECTOR;

ADENOVIRUS; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIZATION; ELECTRON MICROSCOPY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CARMUSTINE; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, COMPLEMENTARY; DOWN-REGULATION; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; TUMOR CELLS, CULTURED;

EID: 0032948143     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Steward, D. J. The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat. Rev., 16: 129-160, 1989.
2. Conrad, C. A., Milosavlijevic, V. P., and Yung, W. K. A. Advances in chemotherapy for adult primary brain tumors. Neurosurg. Clin. N. Am., 13: 795-812, 1995.
3. Stewart, D. J. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J. Neurooncol., 20: 121-139, 1994.
4. Donelli, M. G., Zucchetti, M., and D'Incalci, M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother. Pharmacol., 30: 251-260, 1992.
5. Bartus, R. T., Elliott, P. J., Dean, R. L., Hayward, N. J., Nagle, T. L., Huff, M. R., Snodgrass, P. A., and Blunt, D. G. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp. Neurol., 142: 14-28, 1996.
6. Elliott, P. J., Hayward, N. J., Huff, M. R., Nagle, T. L., Black, K. L., and Bartus, R. T. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp. Neurol., 141: 214-224, 1996.
7. Sanovich, E., Bartus, R. T., Friden, P. M., Dean, R. L., Le, H. Q., and Brightman, M. W. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res., 705: 125-135, 1995.
8. Gralla, J. D., Dwight, S. S., and Poljak, L. G. Formation of blocking lesions in identical DNA sequences by the nitrosourea and platinum classes of anticancer drugs. Cancer Res., 47: 5092-5096, 1987.
9. Srivenugopal, K. S., and Ali-Osman, F. Stimulation and inhibition of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced strand breaks and interstrand cross-linking in Col E1 plasmid deoxyribonucleic acid by polyamines and inorganic cations. Biochem. Pharmacol., 40: 473-479, 1990.
10. 6-alkylguanine-DNA alkyltransferase. Br. J. Cancer, 75: 500-505, 1997.
11. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenesis and therapeutic agents. Cancer Res., 50: 6119-6129, 1990.
12. 6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat. Res., 145: 1-16, 1985.
13. 6-alkylguanine-DNA alkyltransferase. Pharmacol. Ther., 34: 167-179, 1987.
14. 6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res., 53: 3416-3420, 1993.
15. 6-methylguanine-DNA methyltransferase mRNA and its significance as indicator of selective chloroethylnitrosourea chemotherapy. Int. J. Cancer., 69: 420-425, 1996.
16. Zhang, W., Kornblau, S. M., Kobayashi, T., Gambel, A., McClain, C. D., Claxton, D., and Deisseroth, A. B. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogeneous leukemia. Clin. Cancer Res., 1: 1051-1057, 1995.
17. wAF1/CiP1 in human brain tumors. Oncogene, 11: 2021-2028, 1995.
18. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking WAF1/Cip1. Nature (Lond.), 381: 713-716, 1996.
19. McDonald, E. R., Wu, G. S., Waldman, T., and El-Deiry, W. S. Repair defect in p21 WAF1/CIP1 -/- human cancer cells. Cancer Res., 56: 2250-2255, 1996.
20. Ruan, S., Okcu, M. F., Ren, J. P., Chiao, P., Andreeff, M., Levin, V., and Zhang, W. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res., 58: 1538-1543, 1998.
21. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
22. Harper, J. W., Adami, G. R., Wei, N., Keuomarsi, K., and Elledge, S. J. The WAF1/Cip1 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
23. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 90-98, 1994.
24. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
25. Zhang, W., Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travail, S., Deisseroth, A. B., and Mercer, W. E. p53-independent induction of WAF1/Cip1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res., 55: 668-674, 1995.
26. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The WAF1/ Cip1 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369: 574-577, 1994.
27. Wouters, G. B., Giaccia, J. A., Denko, C. N., and Brown, J. M. Loss of p21 Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res., 57: 4703-4706, 1997.
28. Gorospe, M., Cirielli, C., Wang, X., Seth, P., Capogrossi, M. C., and Holbrook, N. J. p21 (Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene, 14: 929-935, 1997.
29. Gorospe, M., Wang, X., Guyton, K. Z., and Holbrook, N. J. Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Mol. Cell. Biol., 16: 6654-6660, 1996.
30. Wang, J., and Walsh, K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science (Washington DC), 273: 359-361, 1996.
31. Kleinerman, D., Zhang, W. W., von Eschenbach, A. C., Lin, S. H., Van, N. T., and Hsieh, J. T. Application of a tumor suppressor gene, C-CAM, in androgen-independent prostate cancer therapy: a preclinical study. Cancer Res., 55: 2831-2836, 1995.
32. Kleinerman, D., Diney, C., Zhang, W. W., Lin, S. H., Van, N. T., and Hsieh, J. T. Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model. Cancer Res., 50: 3431-3435, 1996.